60

PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

Download PDF Report

Upload
trinhque
View
213
Download
0

Embed Size (px)

Citation preview

Page 1: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

Page 2: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

1

Page 3: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

2

Page 4: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

3

Page 5: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

4

Page 6: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

5

Page 7: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

6

Page 8: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

7

Page 9: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

8

Page 10: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

9

Page 11: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

10

Page 12: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

11

Page 13: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

12

Page 14: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

Page 15: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

13

Page 16: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

14

Page 17: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

15

Page 18: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

16

Page 19: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

17

Page 20: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

18

Page 21: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

19

Page 22: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

20

Page 23: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

Page 24: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

21

Page 25: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

22

Page 26: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

23

Page 27: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

24

Page 28: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

25

Page 29: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

26

Page 30: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

27

Page 31: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

28

Page 32: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

29

Page 33: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

Page 34: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

30

Page 35: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

31

Page 36: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

32

Page 37: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

33

Page 38: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

34

Page 39: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

Page 40: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

35

Page 41: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

36

Page 42: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

37

Page 43: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

38

Page 44: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

39

Page 45: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

40

Page 46: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

41

Page 47: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

Page 48: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

42

Page 49: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

43

Page 50: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

44

Page 51: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

45

Page 52: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

1

Page 53: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

46

Page 54: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

47

Page 55: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

48

Page 56: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

49

Page 57: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

50

Page 58: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

Page 59: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

51

Page 60: PowerPoint Presentation AML Once an AML patient progresses to transplant, treatment options are very limited Other AML therapies, such as FLT3/lDH inhibitors, are currently approved

52

Disruption of Wnt/b-Catenin Exerts Antileukemia Activity ... · mutations (FLT3-TKD), are frequently observed in AML (8). These mutations cause ligand-independent activation of the

Disruption of Wnt/b-Catenin Exerts Antileukemia Activity ... · mutations (FLT3-TKD), are frequently observed in AML (8). These mutations cause ligand-independent activation of the

Documents

Charakterisierung von FLT3 assoziierten ... · Charakterisierung von FLT3 assoziierten Signaltransduktionsproteinen und TET2 als epigenetischer Regulator in der akuten myeloischen

Charakterisierung von FLT3 assoziierten ... · Charakterisierung von FLT3 assoziierten Signaltransduktionsproteinen und TET2 als epigenetischer Regulator in der akuten myeloischen

Documents

FLT3 and NPM1 Testing in Acute Myeloid Leukaemia (AML) · PPT file · Web view · 2014-12-09FLT3 and NPM1 Testing in Acute Myeloid Leukaemia Louise Stanley Northern Genetics Service

FLT3 and NPM1 Testing in Acute Myeloid Leukaemia (AML) · PPT file · Web view · 2014-12-09FLT3 and NPM1 Testing in Acute Myeloid Leukaemia Louise Stanley Northern Genetics Service

Documents

All patients with FLT3 mutant AML should receive ... · AML should receive midostaurin-based induction therapy: of course ... MPD in murine model. Mutant ... (31.7-NE); PBO 25.6 (18.6-42.9)

All patients with FLT3 mutant AML should receive ... · AML should receive midostaurin-based induction therapy: of course ... MPD in murine model. Mutant ... (31.7-NE); PBO 25.6 (18.6-42.9)

Documents

Proofs of Principle: clarifying past developments & Innovation and Acceleration for ... · 2020. 2. 19. · RR AML with FLT3 mutation as monotherapy: Dhillon S, Drugs. 2019 Feb 5

Proofs of Principle: clarifying past developments & Innovation and Acceleration for ... · 2020. 2. 19. · RR AML with FLT3 mutation as monotherapy: Dhillon S, Drugs. 2019 Feb 5

Documents

$#3695 Population Pharmacokinetics of Crenolanib, a Type I ... · 18/05/2020 · of crenolanib in patients with relapsed or refractory FLT3+ AML. Methods: Serum blood samples were$

#3695 Population Pharmacokinetics of Crenolanib, a Type I ... · 18/05/2020 · of crenolanib in patients with relapsed or refractory FLT3+ AML. Methods: Serum blood samples were

Documents

PEVONEDISTAT (TAK‐924): A POTENTIAL NEW TREATMENT FOR … · 14.11.2019 · (AML only) BCL2 IDH1/2 FLT3 Intensive Chemotherapy Stem Cell Transplant (Only curative treatment) ≤

PEVONEDISTAT (TAK‐924): A POTENTIAL NEW TREATMENT FOR … · 14.11.2019 · (AML only) BCL2 IDH1/2 FLT3 Intensive Chemotherapy Stem Cell Transplant (Only curative treatment) ≤

Documents

Acute Leukemia - prIME Oncology...Prognostic Impact of NPM1/FLT3-ITD Genotypes From Randomized Patients With Acute Myeloid Leukemia (AML) Treated Within the International RATIFY Study

Acute Leukemia - prIME Oncology...Prognostic Impact of NPM1/FLT3-ITD Genotypes From Randomized Patients With Acute Myeloid Leukemia (AML) Treated Within the International RATIFY Study

Documents

LDH Secondary School

LDH Secondary School

Documents

FLT3 INHIBITORS IN THE TREATMENT OF FLT3/ITD AML: …€¦ · Another potential advantage of crenolanib is its reduced inhibition of c-Kit compared to quizartinib. In progenitor cell

FLT3 INHIBITORS IN THE TREATMENT OF FLT3/ITD AML: …€¦ · Another potential advantage of crenolanib is its reduced inhibition of c-Kit compared to quizartinib. In progenitor cell

Documents

en Leucemia Mieloide Aguda FLT3 positiva

en Leucemia Mieloide Aguda FLT3 positiva

Documents

LDH lactato deshidrogenas

LDH lactato deshidrogenas

Documents

Hemispatial Neglect LDH

Hemispatial Neglect LDH

Documents

Adaptation to TKI Treatment Reactivates ERK Signaling in ... · promising therapeutic strategy in patients with FLT3/ITD AML. ... Pediatrics, Johns Hopkins University School of Medicine,

Adaptation to TKI Treatment Reactivates ERK Signaling in ... · promising therapeutic strategy in patients with FLT3/ITD AML. ... Pediatrics, Johns Hopkins University School of Medicine,

Documents

Pim kinases modulate resistance to FLT3 tyrosine kinase ...advances.sciencemag.org/content/advances/1/8/e1500221.full.pdf · Pim kinases modulate resistance to FLT3 ... (FLT3) is

Pim kinases modulate resistance to FLT3 tyrosine kinase ...advances.sciencemag.org/content/advances/1/8/e1500221.full.pdf · Pim kinases modulate resistance to FLT3 ... (FLT3) is

Documents

Rundbrief Nr. 6 - kompetenznetz-leukaemie.de · internationalen CALGB 10603 Studie (RATIFY) bei AML mit aktivierenden FLT3 Mutationen umgesetzt (clinical-trials.gov: NCT00651261)

Rundbrief Nr. 6 - kompetenznetz-leukaemie.de · internationalen CALGB 10603 Studie (RATIFY) bei AML mit aktivierenden FLT3 Mutationen umgesetzt (clinical-trials.gov: NCT00651261)

Documents

AML predstavitev kliničnega primera - hematologija.org P... · Molekularna genetika: FLT3 ITD Negativen, FLT3 D835 Negativen; KM-Mutacija v genu NPM1 Pozitiven; KM-WT1/qPCR Pozitiven;

AML predstavitev kliničnega primera - hematologija.org P... · Molekularna genetika: FLT3 ITD Negativen, FLT3 D835 Negativen; KM-Mutacija v genu NPM1 Pozitiven; KM-WT1/qPCR Pozitiven;

Documents

Acute Leukemia and the FLT3 Receptor

Acute Leukemia and the FLT3 Receptor

Documents

Research Paper Identification of the key genes and ... · therapeutic target for AML [8, 9]. FLT3 inhibitors have approved for clinical use for mutant FLT3-positive AML in Japan and/or

Research Paper Identification of the key genes and ... · therapeutic target for AML [8, 9]. FLT3 inhibitors have approved for clinical use for mutant FLT3-positive AML in Japan and/or

Documents

Aberrante Aktivierung der Rezeptortyrosinkinase FLT3 in ... · “FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression

Aberrante Aktivierung der Rezeptortyrosinkinase FLT3 in ... · “FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression

Documents

Technical Data Sheet LeukoStrat CDx FLT3 Mutation Assay · LeukoStrat® CDx FLT3 Mutation Assay 280390 Rev. D – Apr. 2017 . Technical Data Sheet . LeukoStrat ® CDx . FLT3. Mutation

Technical Data Sheet LeukoStrat CDx FLT3 Mutation Assay · LeukoStrat® CDx FLT3 Mutation Assay 280390 Rev. D – Apr. 2017 . Technical Data Sheet . LeukoStrat ® CDx . FLT3. Mutation

Documents

Documents

Next Generation Sequencing of Hematologic Neoplasms · Spectrum of mutations in myeloid malignancies AML, MDS, MPN and MDS/MPN overlap disorders FLT3 KIT JAK2 MPL KRAS/NRAS PTPN11

Next Generation Sequencing of Hematologic Neoplasms · Spectrum of mutations in myeloid malignancies AML, MDS, MPN and MDS/MPN overlap disorders FLT3 KIT JAK2 MPL KRAS/NRAS PTPN11

Documents

Education

LO onko 1801 f - hzl.insel.ch · Phase-III-Studie RATIFY nun als Therapie - standard bei m FLT3-AML-Patienten ange - sehen werden kann. 9, 10 Midostaurin wur - de in der Kombination

LO onko 1801 f - hzl.insel.ch · Phase-III-Studie RATIFY nun als Therapie - standard bei m FLT3-AML-Patienten ange - sehen werden kann. 9, 10 Midostaurin wur - de in der Kombination

Documents

ISSN 2218-4333 World Journal of · the most common genetic mutation in acute myeloid leukemia (AML) and represents an attractive therapeutic target. Targeted therapy with FLT3 inhibitors

ISSN 2218-4333 World Journal of · the most common genetic mutation in acute myeloid leukemia (AML) and represents an attractive therapeutic target. Targeted therapy with FLT3 inhibitors

Documents

"FLT3-ITD and FLT3 Inhibitors in the Setting of Allogeneic Stem Cell Transplantation for AML"

"FLT3-ITD and FLT3 Inhibitors in the Setting of Allogeneic Stem Cell Transplantation for AML"

Documents

エアツールコンプレッサ - Kyosei Rentemu Co Ltd...φ50〜65 （5ピッチ）商品コード LGF 04500 LGG 07000 LGF 09000 LDH 20002 LDH 15002 LDH 20002 LDH 30002 メーカー

エアツールコンプレッサ - Kyosei Rentemu Co Ltd...φ50〜65 （5ピッチ）商品コード LGF 04500 LGG 07000 LGF 09000 LDH 20002 LDH 15002 LDH 20002 LDH 30002 メーカー

Documents

ATM/G6PD-driven redox metabolism promotes …ATM and G6PD Are Synthetic Lethal on FLT3 Inhibition in FLT3-ITD+ AML Cells. To identify genes whose suppression sensitizes FLT3-ITD+ AML

ATM/G6PD-driven redox metabolism promotes …ATM and G6PD Are Synthetic Lethal on FLT3 Inhibition in FLT3-ITD+ AML Cells. To identify genes whose suppression sensitizes FLT3-ITD+ AML

Documents

Research Article Mutation of NPM1 and FLT3 Genes in ...downloads.hindawi.com/journals/dm/2013/582569.pdfmechanism of leukemogenesis. 1. Introduction Acute myeloid leukemia (AML) develops

Research Article Mutation of NPM1 and FLT3 Genes in ...downloads.hindawi.com/journals/dm/2013/582569.pdfmechanism of leukemogenesis. 1. Introduction Acute myeloid leukemia (AML) develops

Documents